Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

An anonymous reader shared this report from CNBC:Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly 2,000 women in the trial who received the lenacapavir shot had contracted HIV by an interim analysis, prompting the independent data monitoring committee to recommend Gilead unblind the Phase 3 trial and offer the treatment to everyone in the study. Other participants had received standard daily pills. The company expects to share more data by early next year, the article adds, and if its results are positive, the company could bring its drug to the market as soon as late 2025. (By Fridayt the company's stock price had risen nearly 12%.) There's already other HIV-preventing options, the article points out, but they're taken by "only a little more than one-third of people in the U.S. who could benefit...according to data from the Centers for Disease Control and Prevention." Part of the problem? "Daily pills dominate the market, but drugmakers are now focusing on developing longer-acting shots... Health policymakers and advocates hope longer-acting options could reach people who can't or don't want to take a daily pill and better prevent the spread of a virus that caused about 1 million new infections globally in 2022."

Read more of this story at Slashdot.